# A Study of LY2623091 in Participants With High Blood Pressure

> **NCT02194465** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 304 (actual)

## Conditions studied

- Primary Hypertension

## Interventions

- **DRUG:** LY2623091
- **DRUG:** Tadalafil
- **DRUG:** Spironolactone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02194465
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2020-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194465, "A Study of LY2623091 in Participants With High Blood Pressure". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02194465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*